The activation of T cells by antigens or mitogens leads to the secretion of cytokines and enzymes that shape the inflammatory response. Among these molecular mediators of inflammation is a heparanase enzyme that degrades the heparan sulfate scaffold of the extracellular matrix (ECM). Activated T cells use heparanase to penetrate the ECM and gain access to the tissues. We now report that among the breakdown products of the ECM generated by heparanase is a trisulfated disaccharide that can inhibit delayed-type hypersensitivity (DTH) in mice. This inhibition of T-cell mediated inflammation in vivo was associated with an inhibitory effect of the disaccharide on the production of biologically active tumor necrosis factor a (TNF-a) by activated T cells in vitro; the trisulfated disaccharide did not affect T-cell viability or responsiveness generally. Both the in vivo and in vitro effects of the disaccharide manifested a bellshaped dose-response curve. The inhibitory effects of the trisulfated disaccharide were lost if the sulfate groups were removed. Thus, the disaccharide, which may be a natural product of inflammation, can regulate the functional nature of the response by the T cell to activation. Such a feedback control mechanism could enable the T cell to assess the extent of tissue degradation and adjust its behavior accordingly.
heparanase is a trisulfated disaccharide that can inhibit delayed-type hypersensitivity (DTH) in mice. This inhibition of T-cell mediated inflammation in vivo was associated with an inhibitory effect of the disaccharide on the production of biologically active tumor necrosis factor a (TNF-a) by activated T cells in vitro; the trisulfated disaccharide did not affect T-cell viability or responsiveness generally. Both the in vivo and in vitro effects of the disaccharide manifested a bellshaped dose-response curve. The inhibitory effects of the trisulfated disaccharide were lost if the sulfate groups were removed. Thus, the disaccharide, which may be a natural product of inflammation, can regulate the functional nature of the response by the T cell to activation. Such a feedback control mechanism could enable the T cell to assess the extent of tissue degradation and adjust its behavior accordingly.
Some years ago, we reported that activated T cells secreted heparanase, an enzyme that degrades the heparan-sulfate component of the extracellular matrix (ECM; refS. 1 
and 2).
The expression of heparanase by T cells, unlike that by tumor cells, was found to be tightly regulated by contact with specific antigen or mitogen. Naive T cells responded to activation by synthesizing heparanase de novo but memory T cells were able to release heparanase from preformed stores within minutes of contact with antigen (2) .
In addition to the positive induction of heparanase expression by T-cell activators, heparanase expression was also found to be inhibitable by heparin (3) (4) (5) (6) . Heparin is very similar chemically to heparan sulfate, the natural substrate of heparanase, and it was proposed that heparin, by occupying the binding site of the enzyme, may act as a competitive inhibitor of heparanase activity (3, 5, 6) . However, we found that low doses of heparin appeared to act directly on T cells to inhibit their release of heparanase (4, 5) . Heparin is composed of different sulfated sugar molecules, and the saccharide moieties that inhibit T-cell heparanase release differ from those that inhibit blood coagulation (4) . We reasoned that the T-cell inhibitory molecules in heparin might actually mimic molecules produced by the action of heparanase on its natural substrate heparan sulfate. We report here the isolation of a trisulfated disaccharide generated by the action of heparanase on the ECM (ECM disaccharide). Administration of nanogram amounts of ECM disaccharide suppresses T-cell mediated reactivity in vivo. Incubation of T cells with the ECM disaccharide inhibits T-cell production of the active form of tumor necrosis factor (TNF)-a, a major inflammatory cytokine.
MATERIALS AND METHODS
Heparanase. Mammalian heparanases have not yet been cloned; because T-cell heparanase was not available in quantity, we used heparanase obtained from human placentas. The heparanase enzyme was prepared and purified to >3.4 x 105-fold by ammonium sulfate precipitation followed by sequential chromatographies on carboxymethyl-, heparin-, and Con A-Sepharose columns (RAD Chemicals, Ness Ziona, Israel) by modifying the technique of Oosta et at (7) . The specific activity of the heparanase was determined, as described, by its ability to release 35S04-labeled fragments of heparan sulfate from the ECM (3, 4) .
Preparation of ECM Disaccharide. ECM-coated plates were prepared from bovine corneal endothelial cells as described (5). Each ECM-coated plate was incubated for 48 h at 37°C with 20 ,ul of mammalian heparanase (0.5 mg/ml) in 1 ml of phosphate citrate buffer (18 mM citric acid/64 mM Na2HPO4/50 mM NaCl/1 mM CaCl2/1 mM dithiothreitol, pH 6.2). The culture medium containing the ECM heparan sulfate degradation products was then collected and applied to a Sepharose 4B column (0.7 x 35 cm). The mobile phase was phosphate citrate buffer at a flow rate of 5 ml/h. Fractions of 1.6 ml were collected and monitored at 206 nm to detect oligosaccharides (Fig. 1A) or at 232 nm to detect unsaturated disaccharides. Quantitation of the uronic acid containing disaccharides was done by using the carbazole assay (8) . The lower molecular weight fractions, fractions 5 and 6, of the Sepharose 4B peak were combined and freeze-dried, and the powder was resuspended in 10% of the initial volume. The disaccharide was then isolated from the elution profile by using HPLC gel-filtration chromatography followed by HPLC ionexchange chromatography. Samples of 0.1 ml were injected into an HPLC column [Toyo Soda (Tokyo) TSK-Gel G3000 SW; 7.5 mm x 50 cm; and G2000 SW; 7.5 mm x 50 cm; in series with a 7.5 mm x 10 cm guard column from Phenomenex (Belmont, CA)]. The mobile phase was 0.5 M NaCl at a flow rate of 1 ml/min. Fractions (1 ml) were collected and monitored at 206 and 232 nm. The column was calibrated with heparin-oligosaccharide standards (Seikagaku Kogyo, Tokyo). The peak labeled pl in Fig. 1B, having 13 -glucuronide specificity of placental heparanase, leads to the tentative conclusion that the ECM disaccharide has a glucosamine at the nonreducing end in an a configuration attached 1-4 to a glucuronide acid residue at the reducing end. The complete identification and the organic synthesis of the proposed molecule will be published elsewhere.
A desulfated disaccharide was obtained by incubating some of the disaccharide of peak A23/4 for 4 days at room temperature at pH 3.5. The nonsulfated disaccharide was isolated by its shorter retention time on the Sax-HPLC column, which The purified material was resuspended in 2 ml of double deionized water, desalted on a Sephadex G-10 column (26 x 150 mm), and eluted at 1.6 ml/min with double deionized water. Fractions (1 ml) were collected, monitored at 206 nm to detect carbohydrate molecules, and tested for conductivity to determine NaCI content. Desalted fractions were combined, freeze-dried, and resuspended in 1 ml of double deionized H20. A 18.2 ± 0.9 0 uroups of hALB/c mice were injected subcutaneously with heparin, the medium of ECM that had been degraded by incubation with heparanase (crude ECM), or trisulfated disaccharide isolated from the crude ECM (A23/4 or pl; Fig. 1) . A desulfated isolate of A23/4 was also tested. Negative control, the degree of ear swelling caused by challenging naive mice; positive control, the DTH response of sensitized, untreated mice. *P < 0.01, treated vs. untreated (positive control) mice.
Immunology: Lider et aL Fig. 1C ). The T cells were then activated with PHA and the medium was collected and assayed for TNF-a activity by its ability to induce the killing of TNF-a-sensitive CL7 cells. *P < 0.01, comparing the treated groups to the control (none) group.
crude ECM fraction obtained after digestion of the ECM with heparanase was least active: a concentration of 106 pg/mi was optimum. Purification of the low molecular weight fraction by using Sepharose 4B (see Fig. 1A ) led to optimal activity at 100 pg/ml. ECM disaccharide isolated by HPLC gel filtration (HPLC, see TNF-a Bioactivity and TNF-a Protein Concentration. It has been reported that TNF-a may be produced in a biologically inactive form (11) . We therefore tested whether inhibition of TNF-a activity by the ECM disaccharide could be ascribeol to the production of TNF-a in its inactive rather than in its active form. TNF-a was measured by both the bioassay, which reflects TNF-a activity, and the antibody assay, which reflects the concentration of TNF-a protein independent of its activity (Table 4) . It can be seen that incubating T cells with ECM disaccharide led to a 70% decrease in the biological activity of TNF-a secreted by the T cells in response to activation by The effect of ECM disaccharide purified by HPLC ion-exchange chromatography on TNF-a produced by CD4+ human T cells was tested both by bioassay, as described in the legend of Table 3 , and by antibody assay of the concentration of TNF-a protein. *P < 0.01, comparing the treated vs. untreated groups.
PHA. In contrast, the concentration of TNF-a protein measured by the antibody assay was decreased by only 15%. Hence, the magnitude of the decrease in TNF-a activity cannot be attributed to inhibition of release of TNF-a protein but to a decreased activity of the released TNF-a. Therefore, it appears that treatment with the ECM disaccharide leads the T cell to primarily secrete the biologically inactive form of TNF-a, although it also causes a mild decrease in TNF-a protein concentration.
The decrease in TNF-a activity was not accompanied by an inhibition in T-cell responsiveness generally. T cells incubated with concentrations of ECM disaccharide optimal for inhibition of their TNF-a activity incorporated thymidine and underwent blast transformation in response to mitogen or antigen (data not shown). Thus, the effect of the ECM disaccharide on T cells is relatively selective.
DISCUSSION
The interactions between ECM-associated heparan sulfate proteoglycan and adjacent glycoproteins of the ECM stabilize the matrix structure and help to maintain its integrity (3) . Therefore, cleavage of heparan sulfate by heparanase results in the disassembly of the ECM barrier, enabling leukocyte migration into inflamed tissues. The results presented here indicaie that heparan sulfate not only can serve as a structural element but also can provide regulatory signals cleaved from its own substance.
The heparanase secreted by T cells has not been cloned and was not available in quantities sufficient to be used for our studies. However, it seems that T-cell heparanase and placental heparanase are the same in terms of molecular weight, pH dependency, and substrate specificity; moreover, they both digest the ECM to generate similar breakdown products (3, 12) . Indeed, preliminary experiments indicate that activated CD4+ T cells can cause the release of the trisulfated disaccharide when incubated with ECM in vitro (unpublished data).
Our working hypothesis, therefore, is that T-cell heparanase, like placental heparanase, is capable of producing the inhibitory trisulfated disaccharide from ECM heparan sulfate. In view of the present results, we propose the scheme illustrated in Fig. 3 . Among the products of activated T cells are cytokines such as TNF-a and enzymes such as heparanase. Both types of molecules participate in the inflammatory response. However, the effects of these molecules can have opposite influences on T-cell reactivity: TNF-a participates in a chain reaction that can upregulate the presentation of antigen and activation signals that further activate T cells; heparanase, in contrast, can generate ECM disaccharide that feeds back to downregulate the production of biologically active TNF-a. Thus, we propose that the same heparanase that enables activated T cells to penetrate the tissues produces a disaccharide signal from the ECM debris that directs the T cells to secrete an inactive form of TNF-a. In this way, negative feedback is inherent in the inflammatory response. The results of prelim- (13) .
The enzymatic activity of heparanase has been shown to cause the release of various growth factors and cytokines bound to heparan sulfate (12, 14) . These factors mediate angiogenesis, the proliferation of smooth muscle cells and fibroblasts, and other processes that follow in the wake of the inflammatory response (3) . Recently 
